Who are DWC202405, DWC202314P's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DWC202313, DWC202314P, DWC202313, DWC202314, DWC202404, DWC202314P.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dwc202405-dwc202314p.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

DWC202405, DWC202314P — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DWC202405, DWC202314P (DWC202405, DWC202314P) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: botulinum toxin type A inhibitor. Area: Neurology.

phase 3 botulinum toxin type A inhibitor botulinum toxin type A Neurology Small molecule Live · refreshed every 30 min

Target snapshot

DWC202405, DWC202314P (DWC202405, DWC202314P) — Daewoong Pharmaceutical Co. LTD.. DWC202405 is a botulinum toxin type A inhibitor.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
DWC202405, DWC202314P TARGET	DWC202405, DWC202314P	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
DWC202313, DWC202314P	DWC202313, DWC202314P	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
DWC202313, DWC202314	DWC202313, DWC202314	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A
DWC202404, DWC202314P	DWC202404, DWC202314P	Daewoong Pharmaceutical Co. LTD.	phase 3	botulinum toxin type A inhibitor	botulinum toxin type A

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (botulinum toxin type A inhibitor class)

Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DWC202405, DWC202314P — Competitive Intelligence Brief. https://druglandscape.com/ci/dwc202405-dwc202314p. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab